A circulating tumor DNA test analyzes small fragments of tumor-derived DNA that enter the bloodstream from prostate cancer cells. It is a type of liquid biopsy, usually performed on plasma from a blood sample, and is most useful in advanced or metastatic prostate cancer. ctDNA testing can identify mutations and other genomic changes that may guide targeted treatment, reveal resistance mechanisms, and sometimes provide information about tumor burden or prognosis. Commonly assessed alterations include BRCA1, BRCA2, ATM, AR, TP53, PTEN, and other genes relevant to prostate cancer. The test is especially helpful when metastatic tissue is difficult to biopsy, as often happens with bone-predominant disease. However, a negative result does not always mean the tumor lacks an alteration because some cancers shed very little DNA into blood. Results can also be confounded by age-related blood-cell mutations called clonal hematopoiesis. ctDNA should therefore be interpreted alongside tissue testing, prior treatments, imaging, PSA, symptoms, and the laboratory’s technical quality measures.
- ctDNA testing is a blood-based way to profile prostate cancer DNA and is most established in metastatic disease, not routine early screening.
- Actionable findings can include BRCA1/2 and other homologous recombination repair alterations, MSI-related changes, and treatment-resistance markers.
- A negative plasma test can be falsely reassuring when the ctDNA fraction is low, especially in low-volume or localized disease.
- Clonal hematopoiesis can create blood-derived mutations that resemble tumor mutations, so laboratory filtering and clinical interpretation matter.
- Serial ctDNA testing can show tumor evolution, but routine treatment changes based only on ctDNA kinetics remain less established than genomic treatment selection.
Table of Contents
- What Circulating Tumor DNA Is
- When ctDNA Testing Is Used
- What a Prostate ctDNA Panel Can Detect
- How to Interpret ctDNA Results
- ctDNA and Treatment Resistance
- Limitations, False Negatives, and Clonal Hematopoiesis
- How ctDNA Fits With Tissue Biopsy and Follow-Up
What Circulating Tumor DNA Is
Blood contains short fragments of DNA released from normal cells as they die. This background material is called cell-free DNA, or cfDNA. In a person with cancer, a portion of cfDNA may come from tumor cells. That tumor-derived portion is called circulating tumor DNA, or ctDNA.
A ctDNA test does not look for whole cancer cells. Instead, it extracts plasma DNA and uses methods such as next-generation sequencing, digital PCR, or other high-sensitivity techniques to identify tumor-associated genomic changes. In advanced prostate cancer, the test can provide a molecular snapshot of cancer DNA from several metastatic sites at once.
That is a major advantage over a single tissue biopsy. A needle biopsy samples one location at one moment. Metastatic prostate cancer can be genetically heterogeneous, meaning different metastases may contain different subclones. ctDNA may capture a mixture of DNA shed from several lesions and can therefore reveal alterations that are absent from an old prostate biopsy.
The amount of ctDNA in plasma is often described as the ctDNA fraction or tumor fraction. Higher fractions generally occur with greater tumor burden and more advanced disease, although the relationship is not exact. Some cancers shed abundant DNA; others shed very little despite visible disease.
ctDNA testing is distinct from a circulating tumor cell test. CTC assays analyze intact cancer cells found in blood, while ctDNA assays analyze fragments of tumor DNA. The two approaches can provide complementary information but are technically different.
It is also different from germline genetic testing. A ctDNA panel is designed primarily to profile the tumor. If it detects a potentially inherited alteration such as BRCA2, a separate blood or saliva germline test may be needed to determine whether the variant is present in all cells and could affect relatives.
When ctDNA Testing Is Used
The strongest clinical role for ctDNA in prostate cancer is genomic profiling of recurrent, metastatic, or metastatic castration-resistant disease. In these settings, molecular results can directly affect treatment options.
A clinician may order ctDNA testing when:
- Metastatic tissue is difficult, risky, or impractical to biopsy.
- Available tumor tissue is old or insufficient for sequencing.
- The cancer has progressed after several therapies and may have evolved new alterations.
- A genomic result is needed to evaluate PARP inhibitor eligibility or another targeted therapy.
- The oncology team wants a current molecular profile rather than relying only on the original diagnostic biopsy.
- Repeat profiling could identify an acquired resistance mechanism or clinical-trial target.
Bone metastases are especially relevant. Prostate cancer commonly spreads to bone, but bone biopsies can be technically challenging and decalcification can damage DNA. A blood-based assay may therefore be a practical alternative.
ctDNA is much less reliable for localized prostate cancer screening or diagnosis. Early tumors often release too little tumor DNA into the bloodstream for consistent detection. PSA, MRI, clinical risk assessment, and prostate biopsy remain the established tools for initial diagnosis. Although methylation, fragmentomics, and other cfDNA approaches are being studied for early detection, they are not yet replacements for the standard diagnostic pathway.
In advanced disease, ctDNA usually forms part of a broader metastatic prostate cancer biomarker panel. The panel may be interpreted alongside germline testing, pathology, PSMA imaging, PSA trend, and clinical progression.
The most useful time to test is when the result could change management. Ordering a broad liquid biopsy without a clear treatment or trial question can produce complicated findings that do not alter care.
What a Prostate ctDNA Panel Can Detect
Modern ctDNA panels can detect several classes of genomic alteration, depending on the assay. These may include single-nucleotide variants, small insertions or deletions, copy-number changes, selected gene rearrangements, and sometimes signatures such as microsatellite instability.
Important prostate cancer genes commonly assessed include:
- BRCA1 and BRCA2, which can predict sensitivity to PARP-directed therapy in appropriate settings.
- ATM, PALB2, CHEK2, CDK12, and other HRR genes, which may affect targeted-treatment or trial eligibility, although response varies by gene.
- AR, the androgen receptor gene, where amplification and certain mutations can emerge under pressure from androgen-receptor pathway inhibitors.
- TP53, RB1, and PTEN, which can provide information about aggressive biology and disease evolution.
- Mismatch repair genes and MSI status, which can identify a small group of tumors that may benefit from immune checkpoint therapy.
A BRCA1 or BRCA2 alteration detected in ctDNA can be particularly important because it may have both treatment and hereditary implications. If the result could be germline, confirmatory testing with a non-tumor specimen is usually appropriate.
AR alterations are especially useful as examples of tumor evolution. Prostate cancer exposed to abiraterone, enzalutamide, or related drugs can acquire androgen-receptor changes that support continued signaling despite therapy. ctDNA can sometimes detect these changes without waiting for a new tissue biopsy.
The report may also provide variant allele frequency, which is the proportion of sequencing reads carrying a particular variant. VAF is not the same as the percentage of cancer in the body. It is influenced by tumor fraction, copy number, clonal structure, and background cfDNA.
Some reports estimate the overall tumor fraction. High ctDNA fraction has repeatedly been associated with poorer outcomes in metastatic prostate cancer, but a prognostic association is not automatically a treatment instruction. The most actionable information usually comes from a validated genomic alteration linked to an available therapy or trial.
How to Interpret ctDNA Results
The first step is to determine whether the sample had enough tumor DNA for the assay to be informative. A report with no detected alterations is very different from a report that specifically states the tumor fraction was adequate and no relevant variants were found.
There are several common result patterns:
| Result pattern | What it can mean | Typical next question |
|---|---|---|
| Actionable pathogenic alteration detected | A tumor change may match an approved therapy or clinical trial | Is the alteration valid for this treatment, and does germline confirmation matter? |
| Resistance-associated alteration detected | The tumor may have evolved under prior therapy | Does the finding change the expected benefit of the next treatment? |
| No actionable alteration, adequate ctDNA | No reportable target was found in the genes and methods tested | Are tissue testing or other biomarkers still needed? |
| Low or undetectable ctDNA fraction | The plasma test may have limited sensitivity | Should tissue sequencing be used instead? |
| Possible blood-cell-derived variant | Clonal hematopoiesis may mimic a tumor mutation | Was matched blood-cell analysis or another confirmation method used? |
A pathogenic variant should be distinguished from a variant of uncertain significance. A VUS is not an established treatment target. The presence of a VUS in BRCA2, ATM, or another well-known gene does not automatically qualify the tumor as HRR deficient.
A negative result also needs restraint. If the ctDNA fraction is very low, the assay may simply not have enough tumor material to detect an alteration. This is particularly important when a targeted therapy decision depends on finding a mutation. In that situation, tissue sequencing may still be appropriate.
The test can also identify a potentially germline variant. Because plasma contains DNA from both normal and tumor cells, tumor-only interpretation cannot always determine inheritance. A pathogenic ATM finding, BRCA finding, or another hereditary-cancer-associated variant may need dedicated germline confirmation and genetic counseling.
ctDNA and Treatment Resistance
One of the most promising features of ctDNA is that it can be repeated over time. A new blood sample may reveal molecular changes that were absent before treatment, providing a window into acquired resistance.
Examples include:
- Androgen receptor alterations emerging during androgen-receptor pathway therapy.
- BRCA reversion mutations that restore part of BRCA function and can contribute to PARP inhibitor resistance.
- Changes in TP53, RB1, PTEN, or other pathways associated with aggressive tumor evolution.
- Shifts in the relative abundance of different tumor clones during therapy.
This dynamic information is attractive because conventional PSA or imaging can show that cancer is progressing without explaining why. ctDNA can sometimes add a molecular explanation.
However, resistance markers are not all equally validated for routine treatment selection. The fact that a genomic change is biologically associated with resistance does not always mean there is an approved alternative treatment specifically directed at that change.
Researchers are also studying ctDNA kinetics—how tumor fraction or individual variants rise or fall soon after treatment starts. Falling ctDNA often correlates with response, while persistent or rising ctDNA can indicate poor prognosis or early resistance. A 2024 study in metastatic castration-resistant prostate cancer found that ctDNA monitoring added information beyond PSA.
Even so, routine treatment discontinuation based only on an early ctDNA rise is not yet a universal standard. Imaging, symptoms, PSA, treatment duration, and known response patterns still matter. ctDNA kinetics are better viewed as an emerging monitoring tool than as an automatic switch signal.
Limitations, False Negatives, and Clonal Hematopoiesis
ctDNA testing has important limitations that can change the meaning of a report.
Low tumor shedding is the biggest cause of false-negative results. Localized or low-volume prostate cancer may contribute only a tiny fraction of plasma DNA. Even in metastatic disease, some patients have little detectable ctDNA. A negative result is therefore strongest when the laboratory confirms an adequate tumor fraction or another measure of assay informativeness.
Clonal hematopoiesis can create false-positive tumor calls. As people age, normal blood-forming stem cells can acquire mutations and expand into clones. Their DNA enters plasma and can be mistaken for tumor DNA. This is especially relevant because many men with advanced prostate cancer are older and may have received prior therapies. Good assays use bioinformatic filters, matched white-blood-cell sequencing, or other methods to reduce this problem.
Not every detected alteration is actionable. Large panels often report variants that have uncertain significance or limited evidence in prostate cancer. More information is not always more useful.
Copy-number detection can be difficult at low ctDNA fractions. Amplifications and deletions may require more tumor DNA than simple point mutations to call reliably.
A liquid biopsy cannot replace pathology. ctDNA cannot assign a Gleason Grade Group, confirm neuroendocrine morphology, or show microscopic tissue architecture. If a change in tumor phenotype is suspected, tissue biopsy may still be necessary.
Results depend on timing. A sample drawn while disease burden is very low can be uninformative, while a later sample at progression may reveal much more. Recent treatment can also shift the proportion of tumor DNA in blood.
These limitations explain why ctDNA and tissue testing are often complementary rather than competitors.
One of the most important quality measures behind a liquid-biopsy result is the amount of tumor DNA actually present in the sample. Advanced cancers with a large metastatic burden often shed more ctDNA than small-volume or well-controlled disease. When the tumor fraction is very low, a laboratory may not detect alterations that truly exist. A report described as “no actionable alteration detected” is therefore not always equivalent to a biologically negative tumor.
This is particularly relevant after a strong treatment response, in bone-predominant disease, or when the blood sample contains very little cancer-derived DNA. If a negative result conflicts with the clinical picture and an actionable mutation would change therapy, tissue sequencing from an adequate tumor specimen may still be appropriate. The reverse is also true: ctDNA can sometimes reveal alterations from multiple metastatic sites that a single old tissue block did not capture.
Serial ctDNA measurements are being studied as markers of treatment response and emerging resistance. Falling ctDNA levels during effective therapy are generally favorable, while rising levels can precede or accompany progression. However, changes in ctDNA should not be used alone to stop or switch a proven therapy outside an evidence-based clinical context; PSA, symptoms, imaging, treatment duration, and the reliability of the assay remain essential.
How ctDNA Fits With Tissue Biopsy and Follow-Up
The practical choice between ctDNA and tissue sequencing depends on what information is needed and what specimen is available.
ctDNA is attractive when a fresh tissue biopsy is difficult, when multiple metastatic sites may be genetically different, or when repeat testing is needed. Tissue is preferable when plasma tumor fraction is low, histology is important, or the blood result is negative despite a strong reason to suspect an actionable alteration.
In some patients, the best strategy is to use both. For example, an archival prostate biopsy may establish the original genomic profile, while a later ctDNA test at metastatic progression reveals new resistance alterations. If plasma testing finds a pathogenic hereditary-cancer gene alteration, germline testing can then clarify inherited risk.
Questions to ask after receiving a ctDNA report include:
- Was the ctDNA fraction high enough for a reliable negative result?
- Which findings are pathogenic and which are VUS results?
- Does any alteration match an approved therapy in my current disease setting?
- Do I need germline confirmation for BRCA1, BRCA2, ATM, or another gene?
- Could any reported variant come from clonal hematopoiesis?
- Would tissue sequencing add information that the plasma test could not provide?
- Is repeat ctDNA testing likely to change management later?
- How does the molecular result fit with PSA, scans, symptoms, and prior treatment response?
ctDNA is one of the most useful modern tools for molecularly characterizing advanced prostate cancer, but its strength is not that it replaces every other test. Its value comes from being minimally invasive, repeatable, and capable of capturing current tumor genomics. When interpreted with tissue pathology and clinical data, it can help turn advanced prostate cancer treatment from a fixed sequence into a more individualized strategy.
References
- Cell-free DNA in prostate cancer and treatment selection 2026 (Review)
- Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis 2026 (Systematic Review)
- Clinical Validity of Circulating Tumor DNA as a Diagnostic Biomarker for Prostate Cancer: A Systematic Review 2026 (Systematic Review)
- Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review 2025 (Systematic Review)
- Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer 2024
Disclaimer
This article is for general education and does not replace individualized oncology or genetic counseling. ctDNA results must be interpreted according to tumor fraction, assay method, variant classification, prior treatment, tissue findings, and the current prostate cancer setting. Do not start, stop, or change treatment based solely on a liquid-biopsy result without review by the treating oncology team.
